What Paino Treats: Main Uses and Benefits

Paino (Aceclofenac) is generally considered relevant for easing symptoms related to inflammatory or irritative states and physical discomfort across multiple therapeutic domains. Its primary role is to offer supportive symptomatic relief in clinical settings marked by increased discomfort or tension. Its therapeutic indications apply to conditions where symptoms may intensify temporarily and interfere with daily functioning.

This medication is commonly used in conditions characterized by periods of heightened symptoms, particularly those involving episodic or fluctuating manifestations such as Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. It is applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive and interfere with daily comfort, including pain, swelling, and stiffness.

It is relevant in clinical settings that involve acute or unstable symptom patterns. This is commonly used when short-term symptomatic assistance is needed in situations such as low back pain (Lumbago), soft tissue rheumatism, or discomfort following trauma or specific dental pain episodes. By contributing to easing the overall symptom load, it supports patients during difficult episodes by easing distress.

---

Quick Fact: Relevant for Symptoms related to Inflammatory States

Paino (Aceclofenac) eligibility is strictly defined by regulatory guidelines, focusing on pre-existing conditions and population factors. Use is generally restricted to Adults for its approved indications.

Populations for Whom Use is Contraindicated

Aceclofenac must not be used in patients with absolute contraindications, which include:

• Hypersensitivity: Known allergy to Aceclofenac or any other Non-Steroidal Anti-Inflammatory Drug (NSAID) such as aspirin.
• Gastrointestinal History: Active or recurrent history of peptic ulcer/haemorrhage, or a history of GI bleeding or perforation related to prior NSAID therapy.
• Severe Organ Failure: Severe hepatic failure, severe renal failure, or established congestive heart failure (NYHA Class II-IV).
• Established Cardiovascular Disease: Patients with established ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease.
• Pregnancy: Use is contraindicated during the third trimester of pregnancy.

Age and Conditional Use Rules

Population	Official Regulatory Status
Pediatric Population (Under 18)	Not recommended due to lack of clinical data.
Elderly Patients	Permitted, but require caution and monitoring due to increased risk of serious adverse reactions.
Mild Organ Impairment	Permitted in mild renal impairment; dose reduction and surveillance required for mild-to-moderate hepatic impairment.
Breastfeeding	Use should generally be avoided (not recommended).

Eligibility also requires careful consideration for patients with cardiovascular risk factors, mild heart failure (NYHA Class I), or a history of conditions like Crohn's Disease or Ulcerative Colitis.

️ Interaction Map: Interactions with other medicines and products — official regulatory information for Paino (Aceclofenac)

---

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anticoagulants, Anti-platelet Agents, Selective Serotonin Reuptake Inhibitors (SSRIs), Anti-hypertensives, Diuretics, Cardiac Glycosides, and Immunosuppressants.
Specific interacting medicines (if explicitly listed)	Aspirin, Mifepristone, Lithium, Methotrexate, and Zidovudine.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic Interaction (Reduced Elimination) and Pharmacodynamic/Functional Interaction (Reduced efficacy and increased additive toxicity).
Timing-based interaction rules (if applicable)	Use is restricted for eight to twelve days following Mifepristone administration; caution is advised when administered within 24 hours of Methotrexate.
Population-specific interaction notes (if applicable)	Elderly patients face an increased risk of renal function deterioration when co-administered with certain anti-hypertensives.
Interaction-related restrictions	Concomitant use with other NSAIDs, including COX-2 selective inhibitors, must be avoided.

---

Interaction Classifications (High-Level)

Category	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Contraindicated Combination (Mifepristone), Use Must Be Avoided (Other NSAIDs), Use with Caution / Monitoring Required (Lithium, Anticoagulants, Diuretics).
Regulatory basis (EMA / FDA / etc.)	Information derived from Summary of Product Characteristics (SmPC) and equivalent government prescribing information.
Interaction-context constraints (as defined in official documents)	Specific monitoring of serum potassium is required with potassium-sparing diuretics.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with Lithium and Methotrexate decreases their elimination, which increases their plasma levels and potential for toxicity.
• Concomitant use with Anticoagulants, SSRIs, or Systemic Corticosteroids leads to a formally documented increased risk of gastrointestinal bleeding.
• The efficacy of Anti-hypertensives and Diuretics is reduced, and the risk of nephrotoxicity is increased with co-administration, including with Ciclosporin.

Connection to the overall interaction profile (4 sentences):

Regulatory documents define the interaction structure primarily through identifying medicines that pose a risk of reduced clearance, such as Lithium and Methotrexate, or pharmacodynamic interactions that either lessen therapeutic efficacy or create additive toxicity risks. This includes explicit restrictions such as the need to avoid combination with other NSAIDs and the mandatory time separation rule following Mifepristone administration. The profile highlights that combinations affecting renal function require heightened clinical awareness and monitoring.

How Paino Works: Mechanism of Action

---

Blocking the COX-2 Enzyme and Prostaglandin Synthesis

Paino's primary mechanism involves acting as a competitive inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. This enzyme mediates the synthesis of prostaglandins (PGE₂) from Arachidonic Acid. By preferentially blocking COX-2, the drug interrupts the early molecular steps of the inflammatory cascade, leading to a reduction in the concentration of these key chemical mediators at the affected site. The parent compound is metabolized to Diclofenac, which complements this action by providing sustained, non-selective inhibition of the cyclooxygenase pathway.

---

️ Physiological Consequence: Adjusting Signaling Pathways

Beyond enzymatic blockade, the drug influences the inflammatory cascade by modulating the expression of pro-inflammatory cytokines (like IL-1β) and interfering with cell adhesion molecules on immune cells, thereby limiting the recruitment of these cells. The systemic reduction of prostaglandins decreases local vasodilation and the sensitization of sensory nerve endings. This physiological change reduces localized tissue reaction and modulates signaling within the pain pathways. The total effect is sustained by the complementary action of the parent drug and the active metabolite.

Paino, which contains the active substance Aceclofenac, is governed by administration protocols detailing the route, quantity, frequency, and context of use. The medicine is administered via two approved routes: oral delivery as a film-coated tablet for systemic absorption, and topical application as a cream or ointment for localized effect.

Standardized Dosing and Administration

The standardized adult regimen for the oral film-coated tablet is 100 mg taken twice daily, resulting in a maximum daily systemic intake of 200 mg/ day. The tablets must be swallowed whole with sufficient fluid and are not permitted to be crushed or chewed, maintaining the integrity of the dosage form. The administration is flexible regarding food, as the tablet may be taken with or without food. For topical preparations, application is typically recommended two to three times per day to the affected area.

Contextual and Population Adjustments

Usage is patterned over time for both short-term episodes and long-term management of chronic conditions. A critical administrative adjustment is required for patients with confirmed mild-to-moderate hepatic impairment: their systemic daily dose must be reduced to 100 mg taken once daily. While no routine dose adjustment is specified for older adults, careful administration and monitoring are advised. These instructions define the standardized approach to using the medicine.

Research evidence / Overview of studies for Paino (Aceclofenac)

---

Evidence for Use in Chronic Joint Conditions

Research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS), involves controlled clinical trials. These studies, often short- to intermediate-term, were applied in studies examining patient-reported experiences among adults with confirmed diagnoses. Researchers focused on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. This research explores outcomes related to symptomatic changes when Aceclofenac was studied for these conditions.

In these trials, the research highlights changes measured during the study period for outcomes linked to inflammatory or irritative states, such as joint swelling and tenderness. Furthermore, comparative trials research examined Paino against other treatments. Although short-term changes in functional and symptomatic outcomes were recorded, the long-term effects are not fully established.

---

Evidence for Use in Acute Pain and Symptom Management

The evidence base for studies evaluating outcomes related to acute and temporary symptoms, such as in episodes of low back pain and post-procedural dental pain, primarily consists of short-term controlled trials. These studies explored episodic or acute changes and were applied in research contexts involving fluctuating or unstable symptoms. The populations studied were adults who presented with conditions associated with acute or disruptive episodes.

Research reports described measurable changes in pain intensity scores during the observation period. Some comparative data described patterns of outcomes that were observed in studies comparing Paino to certain other non-opioid analgesics. What remains uncertain is the long-term research scope for recurrent or chronic localized conditions. Follow-up durations were limited, often restricted to a few weeks, meaning evidence derived from settings with varying symptom burdens does not provide a complete picture of long-term patterns.

---

What is Still Uncertain About Paino Research

A key limitation in the research is that comparative evidence is lacking in some areas, particularly large-scale trials directly comparing Paino against all currently available alternative treatments for chronic use. Overall, although a body of evidence exists, limitations such as modest sample sizes in certain trials and the limited information for long-term outcomes mean that research is ongoing to further clarify the comprehensive scope of Paino's evidence within the broader therapeutic landscape.

Key Studies & References

1. Aceclofenac 100 mg film-coated tablets: UK/H/3717/001/DC Public Assessment Report (Regulatory Review)
2. A Review of Aceclofenac: Analgesic and Anti-Inflammatory Effects on Musculoskeletal Disorders (Systematic Review/Meta-analysis)

Common questions about Paino (FAQ)

Q: How quickly does Paino usually start to work?

A: According to official product information, the maximum amount of the drug in the bloodstream is typically reached within one to three hours after taking an oral tablet. This measurement is known as T max in pharmacological studies and is an indication of when the highest concentration of the drug is circulating. The presence of food may affect the speed at which the drug is absorbed.

---

Q: How long do the effects of Paino typically last?

A: Studies examining the clearance of the medicine from the body show that the plasma half-life is approximately three to five hours. The half-life describes the time required for the amount of active substance in the blood to decrease by half. The duration of symptomatic relief can vary among individuals and may not directly correlate with the half-life.

---

Q: What does the manufacturer advise about taking Paino with alcohol?

A: Regulatory warnings indicate that the consumption of alcohol is advised against while using this medicine. This is because combining the medicine with alcohol may increase the risk of certain side effects, specifically the potential for internal bleeding in the stomach or intestines.

---

Q: Can Paino be taken before driving?

A: Official product information advises that patients should refrain from driving or operating machinery if they experience dizziness, fatigue, or any other disturbances to the central nervous system. Patients who experience these effects are cautioned in official documents to refrain from driving or operating machinery.

---

Q: Does taking Paino cause drowsiness or fatigue?

A: Regulatory documents report that both drowsiness (somnolence) and fatigue (tiredness) are rare possible adverse reactions to the medicine. The official warning regarding driving is based on the possibility of these effects occurring.

---

Q: Can Paino interact with blood pressure medications?

A: Yes, regulatory documents describe a potential interaction with certain anti-hypertensive drugs, which are used to manage high blood pressure. This interaction indicates that the medicine may reduce the effectiveness of blood pressure treatments, and this combination is typically subject to clinical review and monitoring.

---

Q: Is there a generic version of Paino available?

A: The active substance in Paino is Aceclofenac, and this chemical is widely available under its non-proprietary chemical name from various manufacturers. As a result, the substance is included in many national drug registries as a recognized active substance.

---

Q: Is Paino considered addictive or habit-forming?

A: No. The medicine is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). According to official health information, it has not been reported to have habit-forming tendencies.

---

Q: Are there different forms or strengths of Paino?

A: The medicine is primarily supplied as a 100 mg film-coated tablet for systemic relief via oral administration. It is also formulated into topical preparations, such as creams or ointments, designed for localized application.

---

Q: Does Paino have any known serious but rare side effects?

A: Yes. The regulatory safety profile documents serious adverse reactions that are classified as rare, meaning they occur infrequently. Examples include severe allergic reactions (anaphylaxis) and severe skin reactions like Stevens-Johnson Syndrome (SJS).

---

Q: Is Paino used for chronic or acute conditions?

A: According to its official indications, the medicine is used for the symptomatic relief of both chronic inflammatory conditions, such as rheumatoid arthritis, and acute conditions, such such as short-term inflammatory episodes.

---

Q: Is Paino listed on any international essential medicines lists?

A: The active substance in Paino, Aceclofenac, is recognized globally as a therapeutic option. It is included in a number of national essential medicines lists maintained by government health agencies around the world.

Official Storage Conditions

Paino (Aceclofenac) must be stored at ambient temperatures, specifically below 25 C or 30 C, as indicated on the approved regulatory label. The medicine must not be frozen and should be protected from both light and moisture to maintain its stability and effectiveness. It is required to keep the product in its original package or outer carton until use. After opening, topical formulations may have a limited in-use stability period (e.g., 30 days) that must be followed.

Child Safety and Disposal

Regulatory documents universally mandate that Paino be stored out of the sight and reach of children.

Expired or unused medicine must not be thrown away via household waste or wastewater. Disposal must follow official guidelines, typically by returning the product to a pharmacist or utilizing an approved drug take-back scheme to protect the environment.